Import substitution development strategy

(redirected from ISI)
Also found in: Dictionary, Thesaurus, Medical, Legal, Acronyms, Encyclopedia, Wikipedia.

Import substitution development strategy

A development strategy followed by many Latin American countries and other LDCs that emphasize import substitution-accomplished through protectionism-as the route to economic growth.

Import Substitution Development Strategy

A development strategy whereby a government restricts or forbids the import of industrial material and subsidizes local material. For example, a country may not allow the import of refined oil and instead encourage development of local oil refineries. The idea behind this strategy is to make a less developed country less dependent on international assistance and foreign direct investment until such time as it is can absorb investment more easily and also trade its own products. This development strategy was followed in Latin America and some other regions for most of the mid and late 20th century. It has its theoretical foundations in Keynesian economics, though some analysts have claimed that each nation industrializing after the United Kingdom has followed some form of import substitution.
Mentioned in ?
References in periodicals archive ?
ISI represents producers of fresh, frozen and salted seafood on international markets, with branches in Iceland, Britain, France, Germany, Lithuania, Poland, Greece, Canada, Italy and Spain.
To experience the ISI difference, or obtain more information, visit their website at: www.
An added benefit of this transaction is that both Argyle Security and ISI are located in San Antonio, which will facilitate the integration process and execution of our mutual growth objectives.
Using its proprietary antisense technology, Isis has created a large pipeline of first-in-class or best-in-class drugs, with over a dozen drugs in mid- to late-stage development.
In just under 8 minutes the iSis can read 1,500 patches for both no-filter and UV-cut measurements.
ABOUT ISIS and BIOGEN Isis and Biogen have a broad strategic alliance focused on leveraging antisense technology to advance the treatment of neurological and neuromuscular disorders.
Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners.
What: Isis Pharmaceuticals' Ibis Division Analyst Day Webcast.
Following the announcement of a manufacturing and distribution agreement between Isis Pharmaceuticals and Bruker Daltonics earlier this year, the companies have taken the next important step towards commercialization of the Ibis T5000 biosensor system by entering the large European markets.
What: Isis Pharmaceuticals' Analyst/Investor Webcast Presentation